All In Biotech

Drug Trial Radar · NCT04884191

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Last checked: Nov 20, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Jul 31, 2017

Primary completion

Sep 4, 2019

Study completion Sep 4, 2019

Sponsor

Lead sponsor
CTI BioPharmaIndustry
Sponsor type
Industry
First posted
May 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.

Conditions

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post- Essential Thrombocythemia Myelofibrosis

Interventions

  • PacritinibDrug

    Pacritinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Spleen Volume Reduction Response (≥ 35%)Time frame: From Baseline to Weeks 12 and 24
  2. Percent Change in Spleen VolumeTime frame: From Baseline to Weeks 12 and 24
  3. Total Symptom Score AnalysisTime frame: From Baseline to Weeks 12 and 24
  4. Patient Global Impression AssessmentTime frame: From Baseline to Weeks 12 and 24

Locations

62 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Stanford Cancer Institute

    Stanford, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Medical Faculty Associates, Inc.

    Washington D.C., District of Columbia

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida

  • Florida Cancer Specialists & Research Institute

    St. Petersburg, Florida

  • Florida Cancer Specialists & Research Institute

    West Palm Beach, Florida

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Saint Agnes Hospital

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Weill Cornell Medical College

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University Hospital

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio School of Medicine

    San Antonio, Texas

  • University of Utah School of Medicine

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • CHU Hopital Sud

    Amiens, France

  • Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez

    Lille, France

  • CHU de Nimes - Hopital Universitaire Caremeau

    Nîmes, France

  • Hôpital Saint-Louis

    Paris, France

  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque

    Pessac, France

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France

  • Centre Hospitalier Universitaire de Toulouse- Hôpital Purpan

    Toulouse, France

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.